Clinical Trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Study acronym: RASolute 303
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Protocol Amendment History 3 changes
notable Trial sites expanded: 13 -> 20 locations 2026-07-22
notable Trial sites expanded: 8 -> 13 locations 2026-06-26
notable Trial sites expanded: 5 -> 8 locations 2026-06-19
Trial Details
NCT Number NCT07491445
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Enrollment 900 participants
Start Date 2026-03-09
Primary Completion 2028-06 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-21